(OTC: HSXI), (NASDAQ: HEPH), (OTCBB: BIPH), (PINKSHEETS: JCDS).

Turning Pennies into dollars: (OTC: HSXI), (NASDAQ: HEPH), (OTCBB: BIPH), (PINKSHEETS: JCDS).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://hsxi.realpennies.com

HealthSonix, Inc. (OTC: HSXI) (February 5, 2008) announced Tuesday that it has launched a dedicated web site for its ZingiberRx Joint and Muscle cream: www.zingiberRx.com ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.

Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar and Zingiber officinale species for their anti-inflammatory, anti-allergic and pain relieving properties.

"The launch of this web site coincides with on going retail sampling and couponing programs being tested in major pharmacy chains." said Dieter Doederlein, Vice President Corporate Development of HealthSonix. "The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. "

The Company is also launching a major online sales and marketing campaign with Google and Yahoo adwords and banner ads on websites that cater to the 50+ population segment: "This new marketing program has been designed to increase awareness and promote direct to consumer sales from our online store." added Doederlein.

HealthSonix, Inc. (OTC: HSXI) (FRANKFURT: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company's patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.

For more info: http://heph.realpennies.com

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH)(February 7, 2008), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced earlier today that it has commenced a Phase I/II clinical trial with its oral drug candidate TRIOLEX (HE3286) in ulcerative colitis (UC) under an Investigational New Drug application (IND) cleared by the U.S. Food and Drug Administration (FDA) for this indication. The Phase I/II dose ranging study will evaluate the safety, tolerance, pharmacokinetics and activity of TRIOLEX when administered orally for 28 days to patients with active, mild-to-moderate UC.

In previously reported data presented at the 3rd International Conference on Autoimmunity last October, TRIOLEX showed significant (p <0.05) benefit in the Wistar rat model of dinitrobenzene sulfonic acid (DNBS) induced colitis, a preclinical model widely used by industry and academia to test agents as potential treatments for UC. DNBS challenged rats with induced colitis were treated orally for seven days with either TRIOLEX or placebo (n=10 per group). At the end of the treatment period, TRIOLEX-treated animals had significantly reduced disease, as judged by reduced colon weight and reduced area of necrosis, compared to the placebo-treated animals. TRIOLEX performed as well as or better than Sulfazalazine, the standard of care used as a positive control in this model.

TRIOLEX is a novel orally bio-available adrenal steroid hormone analogue with anti-inflammatory and insulin sensitizing properties currently in clinical trials under an open IND for the treatment of metabolic disorders. The Company has also been cleared under a separate IND with the FDA to begin clinical trials with TRIOLEX for the treatment of rheumatoid arthritis (RA). A safety and pharmacokinetic phase I/II clinical trial in stable RA patients on methotrexate, a commonly used chemotherapy treatment, is currently planned to begin in the second quarter of 2008. The Company believes that certain aspects of the pathology driving UC are similar to those driving RA. Therefore, data obtained in this UC study could potentially help support the design of the Company's planned Phase II RA clinical study and help to accelerate the development of TRIOLEX for potential use in patients with RA.

Hollis-Eden believes the broad-based anti-inflammatory activity of TRIOLEX may relate to a partial inhibition of the NF-kappaB pathway. NF-kappaB is a transcription factor that controls genes whose products are involved in the inflammatory signaling pathway, including TNF-alpha and IL-6. These cytokines are thought to be involved in the pathogenesis of certain autoimmune diseases such as UC and RA, and are also implicated in the pathogenesis of metabolic diseases, cardiovascular disorders, cancer and in general, diseases associated with aging. Unlike currently prescribed corticosteroids that act through the glucocorticoid receptor to completely block NF-kappaB activation and cause immune suppression and bone loss, preclinical models to date show that TRIOLEX does not interact with the glucocorticoid receptor and only results in a partial inhibition of the NF-kappaB pathway without immune suppression or bone loss.

The blood-drug concentration profiles observed in a previous Phase I study with TRIOLEX were consistent with drug levels in the blood associated with glycemic control and anti-inflammatory activity that the Company has observed in previously reported preclinical models of metabolic disorders and diseases of inflammation, respectively. TRIOLEX also appears to have a longer half-life in humans than in rodents (5-8 hours versus 2 hours, respectively).

"Given the rapid progression of the disease flares and the clearly defined clinical endpoints in UC, this study may potentially enable us to demonstrate activity in humans with a short treatment course of TRIOLEX in an acute inflammatory condition, and thereby accelerate its potential commercialization," said Richard B. Hollis, Chairman and CEO, Hollis-Eden Pharmaceuticals, Inc. "There are certain understood similarities between UC and RA disease processes, so the results from this UC trial should also enable us to optimize our Phase II clinical trial in RA. This strategy could enable the Company to demonstrate the safety and efficacy of TRIOLEX in acute and chronic inflammatory conditions, both of which are treated today with currently prescribed anti-inflammatory drugs." Ulcerative colitis is a chronic inflammation of the large intestine, or colon, and is related to another condition of inflammation of the intestines called Crohn's disease. UC and Crohn's disease are frequently referred to together as inflammatory bowel disease, or IBD. UC and Crohn's disease together affect approximately 500,000 to 2 million people in the United States. Current first-line anti-inflammatory drugs for the treatment of UC are topical 5-ASA compounds such as sulfasalazine-, olsalazine- and mesalimine-based treatments. Additionally, UC is treated with corticosteroids and immunomodulators.

Hollis-Eden Pharmaceuticals, Inc. is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. Through its Hormonal Signaling Technology Platform, Hollis-Eden is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands from the body's most abundant circulating adrenal steroid. These steroid hormones, designed to restore the biological activity of cellular signaling pathways disrupted by disease and aging, have been demonstrated in humans to possess several properties with potential therapeutic benefit -- they regulate innate and adaptive immunity, reduce nonproductive inflammation and stimulate cell proliferation. The Company's clinical drug development candidates include TRIOLEX (HE3286), a next-generation compound currently in clinical trials for the treatment of metabolic disorders as well as ulcerative colitis and being prepared for clinical trials in rheumatoid arthritis under another IND, and APOPTONE (HE3235), a next-generation compound selected for cancer. In addition to these clinical development candidates, Hollis-Eden has an active research program that is generating additional new clinical leads that are being further evaluated in preclinical models of a number of different diseases. For more information on Hollis-Eden, visit the Company's website at www.holliseden.com.

For more info: http://biph.realpennies.com

Biophan Technologies, Inc. (OTCBB: BIPH)(February 7, 2008), a developer of next-generation biomedical technology, announced earlier today that the Company has named Harold Gubnitsky to the board of directors.

Harold Gubnitsky is executive vice president of XL Techgroup, Inc., a unique value creation company focused on inventing and growing new companies in the biotech, ecotech, and medtech business sectors. Mr. Gubnitsky is a seasoned executive who has worked with and within several large, medium, and small corporations with a wide range of responsibilities spanning executive management and operations.

In 2001, Mr. Gubnitsky founded Semtor Corporation, a technology services company, serving as its CEO. Prior to Semtor, he was an officer and senior executive of Proxicom, a technology business consulting firm with a market capitalization in excess of $1.5 billion. Previously, Mr. Gubnitsky served as vice president of Cambridge Technology Partners where he led numerous vendor/partner relationships and was responsible for selling and managing several Fortune 100 relationships. Prior to Cambridge, Mr. Gubnitsky served as part of the management team at Accenture.

Commenting on the appointment, Biophan CEO John Lanzafame stated, "I am very pleased to welcome Harold to our board. His experience in nurturing and growing new companies in the healthcare space will be invaluable as we continue to evolve and grow Biophan's core business." Added Stan Yakatan, Biophan's chairman, "We are very fortunate to have men of the caliber and expertise of Harold Gubnitsky and Travis E. Baugh, whose appointment we announced yesterday, agree to serve on our board of directors."

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

For more info: http://jcds.realpennies.com

JC Data Solutions, Inc. (PINKSHEETS: JCDS)(February 7, 2008) announced earlier today that through its resellers Precision Products Inc. and MD Point CMS, Inc. have delivered and installed FormGen to Midtown Surgery Center Houston, Texas, Prestonwood Surgery Center in Dallas, Specialty Surgery Center in Dallas, Texas, Slocum Surgery Center Portland, Oregon, Scotts Bluff Surgery Center, Scotts Bluff, Nebraska.

This proprietary software is designed to take the multitude of forms used by the medical field and allow preparation of patient documents in a fraction of the time and provide manpower and costs savings. Utilizing .NET technology and barcode processing, these forms are electronically prepared with patient data allowing users to create, distribute, and communicate documents that automate their information needs.

"As expected this product can and does make an impact on productivity within the medical services organizations that use it," states Cary Allen, CEO, JCDS. "We continue to see sales increase and believe this will continue to be a hot selling product for JCDS for some time to come."

JC Data Solutions is an ACH service provider and a manufacturer of data management systems and services. JCDS solutions are targeted to Healthcare, Attorneys and the Oil and Gas industries.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com